Table 3-2
Changes in five-year observed survival proportions over time by diagnostic group and selected subgroup, ages 0 to 14 at diagnosis, Canada excluding Quebec, 1992-to-1996 period to 2013-to-2017 period — Part 2


Table 3-2
Changes in five-year observed survival proportions over time by diagnostic group and selected subgroup, ages 0 to 14 at diagnosis, Canada excluding Quebec, 1992-to-1996 period to 2013-to-2017 period — Part 2
Table summary
This table displays the results of Changes in five-year observed survival proportions over time by diagnostic group and selected subgroup. The information is grouped by Diagnostic group / subgroup (appearing as row headers), Time period, Change
(% points), 1992-to-1996
to
2013-to-2017, 1992-to-1996
to
2003-to-2007, 2003-to-2007
to
2013-to-2017, 95% CI and P-value (appearing as column headers).
Diagnostic group / subgroup Time period
Change
(% points)		 1992-to-1996
to
2013-to-2017		 Change
(% points)		 1992-to-1996
to
2003-to-2007		 Change
(% points)		 2003-to-2007
to
2013-to-2017
95% CI P-value 95% CI P-value 95% CI P-value
from to from to from to
All groups 7.5 5.6 9.3 < 0.001 6.2 4.3 8.1 < 0.001 1.3 -0.4 3.0 0.134
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases 10.3 7.3 13.3 < 0.001 9.4 6.2 12.5 < 0.001 0.9 -1.7 3.6 0.484
a. Lymphoid leukemias 8.0 5.1 10.8 < 0.001 6.1 3.0 9.1 < 0.001 1.9 -0.5 4.3 0.126
b. Acute myeloid leukemias 16.6 6.4 26.8 0.001 23.5 13.2 33.9 < 0.001 -7.0 -16.9 2.9 0.167
c. Chronic myeloproliferative diseases 35.4 15.7 55.0 < 0.001 32.5 9.9 55.1 0.005 2.9 -12.5 18.2 0.714
II. Lymphomas and reticuloendothelial neoplasms 7.5 2.9 12.1 0.001 7.1 2.3 12.0 0.004 0.4 -3.3 4.1 0.839
a. Hodgkin lymphomas 9.4 4.1 14.7 < 0.001 9.5 4.3 14.8 0.000 -0.1 -2.1 1.9 0.934
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 7.0 -2.8 16.8 0.159 12.8 2.8 22.9 0.012 -5.8 -13.6 2.0 0.143
c. Burkitt lymphoma 1.6 -7.9 11.1 0.746 -3.8 -15.2 7.6 0.515 5.4 -5.2 16.0 0.321
d. Miscellaneous lymphoreticular neoplasms Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period 20.6 2.0 39.3 0.030
III. CNS and miscellaneous intracranial and intraspinal neoplasms 5.2 0.4 10.1 0.034 4.4 -0.5 9.4 0.079 0.8 -4.1 5.6 0.750
a. Ependymomas and choroid plexus tumour 32.1 16.3 47.8 < 0.001 19.8 2.4 37.3 0.026 12.3 -2.9 27.4 0.112
b. Astrocytomas -0.8 -6.6 5.0 0.784 0.4 -5.5 6.3 0.897 -1.2 -7.3 4.9 0.700
c. Intracranial and intraspinal embryonal tumours 16.6 6.5 26.7 0.001 4.1 -6.8 15.0 0.457 12.5 1.8 23.1 0.021
d. Other gliomas -2.8 -16.7 11.1 0.694 15.3 0.6 29.9 0.041 -18.1 -31.8 -4.3 0.010
IV. Neuroblastoma and other peripheral nervous cell tumours 18.8 10.9 26.7 < 0.001 13.5 5.1 21.9 0.002 5.3 -1.7 12.3 0.137
a. Neuroblastoma and ganglioneuroblastoma 19.4 11.5 27.3 < 0.001 13.8 5.3 22.3 0.001 5.6 -1.4 12.7 0.119
V. Retinoblastoma -4.8 -10.8 1.2 0.116 -5.1 -11.3 1.1 0.110 0.3 -7.8 8.4 0.942
VI. Renal tumours 8.7 3.1 14.2 0.002 -1.9 -8.9 5.2 0.603 10.6 4.4 16.7 0.001
a. Nephroblastoma and other nonepithelial renal tumours 9.5 3.8 15.1 0.001 -0.7 -7.9 6.6 0.856 10.1 4.0 16.3 0.001
VII. Hepatic tumours 2.0 -15.5 19.4 0.826 0.5 -17.0 17.9 0.957 1.5 -16.1 19.1 0.870
VIII. Malignant bone tumours -0.9 -11.1 9.2 0.858 -4.9 -15.3 5.4 0.352 4.0 -6.2 14.2 0.445
a. Osteosarcomas -1.3 -16.0 13.5 0.865 3.7 -10.8 18.3 0.616 -5.0 -19.7 9.7 0.503
c. Ewing tumour and related sarcomas of bone 2.6 -13.4 18.5 0.753 -12.1 -28.9 4.6 0.156 14.7 -0.7 30.1 0.061
IX. Soft tissue and other extraosseous sarcomas 0.0 -8.3 8.2 0.991 -2.1 -10.8 6.6 0.638 2.1 -6.6 10.7 0.641
a. Rhabdomyosarcomas 1.6 -10.1 13.4 0.785 -4.3 -17.0 8.4 0.508 5.9 -7.0 18.8 0.367
d. Other specified soft tissue sarcomas -8.2 -22.9 6.6 0.277 -2.2 -17.1 12.8 0.774 -6.0 -20.5 8.5 0.418
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 4.9 -3.2 13.0 0.238 4.8 -3.6 13.1 0.262 0.1 -7.3 7.5 0.975
b. Malignant extracranial and extragonadal germ cell tumours 3.3 -13.0 19.6 0.690 8.5 -6.6 23.5 0.270 -5.1 -17.4 7.1 0.410
c. Malignant gonadal germ cell tumours 3.2 -4.8 11.2 0.431 1.3 -7.5 10.0 0.775 1.9 -5.8 9.7 0.626
XI. Other malignant epithelial neoplasms and malignant melanomas 5.9 -1.7 13.6 0.129 7.9 0.1 15.7 0.047 -2.0 -7.9 4.0 0.517
b. Thyroid carcinomas 2.6 Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period 2.6 Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period 0.0 Note ..: not available for a specific reference period Note ..: not available for a specific reference period Note ..: not available for a specific reference period
f. Other and unspecified carcinomas 11.9 -3.0 26.8 0.117 6.2 -11.7 24.1 0.500 5.8 -9.1 20.6 0.447
XII. Other and unspecified malignant neoplasms -10.9 -31.2 9.5 0.296 2.1 -10.2 14.3 0.743 -12.9 -31.9 6.1 0.182
.. not available for a specific reference period
E Use with caution
F too unreliable to be published
Notes: OSP = observed survival proportion; CI = confidence interval; CNS = central nervous system. OSPs for all groups combined were calculated as a weighted average of sex- and diagnostic-group-specific estimates. Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the Canadian Cancer Registry. All estimates are based on invasive behaviour cases only. OSPs for the 2013-to-2017 period were predicted using the period method. The use of caution is suggested in the interpretation of estimates associated with an unrounded standard error > 0.05 and ≤ 0.10.; if > 0.10, estimates were considered too unreliable to be published. Differences in survival over the full period may not equal the sum of differences for the subperiods because of rounding.
Source: Statistics Canada, Canadian Cancer Registry death linked file (1992 to 2017).

More information

ISSN: 1209-1367

Note of appreciation

Canada owes the success of its statistical system to a long-standing partnership between Statistics Canada, the citizens of Canada, its businesses, governments and other institutions. Accurate and timely statistical information could not be produced without their continued co-operation and goodwill.

Standards of service to the public

Statistics Canada is committed to serving its clients in a prompt, reliable and courteous manner. To this end, the Agency has developed standards of service which its employees observe in serving its clients.

Copyright

Published by authority of the Minister responsible for Statistics Canada.

© Her Majesty the Queen in Right of Canada as represented by the Minister of Industry, 2021

Use of this publication is governed by the Statistics Canada Open Licence Agreement.

Catalogue no. 82-003-X

Frequency: Monthly

Ottawa

Date modified: